Evidence map›Paper›PMID 37670319›Full record

ArticleOrphanet journal of rare diseases2023

Neurodegeneration or dysfunction in Phelan-McDermid syndrome? A multimodal approach with CSF and computational MRI.

Sarah Jesse, Hans-Peter Müller, Hans-Jürgen Huppertz, Stephanie Andres, Albert C Ludolph, Michael Schön, Tobias M Boeckers, Jan Kassubek

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Case Report: Co-occurringFrontiers in genetics · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Sarah JesseDepartment of Neurology, University Hospital Ulm, Oberer Eselsberg 45, D-89081, Ulm, Germany. sarah.jesse@uni-ulm.de.ORCID http://orcid.org/0000-0001-6235-8145
Hans-Peter MüllerDepartment of Neurology, University Hospital Ulm, Oberer Eselsberg 45, D-89081, Ulm, Germany.
Hans-Jürgen HuppertzSwiss Epilepsy Clinic, Hospital Lengg, Zürich, Switzerland.
Stephanie AndresMedicover München Ost MVZ, Humangenetik, Munich, Germany.
Albert C LudolphDepartment of Neurology, University Hospital Ulm, Oberer Eselsberg 45, D-89081, Ulm, Germany.
Michael SchönInstitute of Anatomy and Cell Biology, Ulm University, Ulm, Germany.
Tobias M BoeckersGerman Centre of Neurodegenerative Diseases (DZNE), Ulm, Germany.
Jan KassubekDepartment of Neurology, University Hospital Ulm, Oberer Eselsberg 45, D-89081, Ulm, Germany.
Universität Ulm · DEGerman Center for Neurodegenerative Diseases · DEMedicover · DESwiss Epilepsy Center · CHUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPhelan-McDermid syndrome (PMS) is a rare multisystem disease with global developmental delay and autistic features. Genetically, the disease is based on a heterozygous deletion of chromosome 22q13.3 with involvement of at least part of the SHANK3 gene or heterozygous pathogenic variants in SHANK3. Pathophysiologically, this syndrome has been regarded as a synaptopathy, but current data suggest an additional concept, since axonal functions of neurons are also impaired, thus, the specific pathophysiological processes in this disease are not yet fully understood. Since symptoms of the autism spectrum, regression, and stagnation in development occur, we investigated whether neuroinflammatory and neurodegenerative processes may also play a role. To this end, we analysed biomarkers in cerebrospinal fluid (CSF) and parameters from magnetic resonance imaging with high-resolution structural T1w volumetry and diffusion tensor imaging analysis in 19 Phelan-McDermid syndrome patients.

resultsCSF showed no inflammation but abnormalities in tau protein and amyloid-ß concentrations, however, with no typical biomarker pattern as in Alzheimer's disease. It could be demonstrated that these CSF changes were correlated with integrity losses of the fibres in the corticospinal tract as well as in the splenium and dorsal part of the cingulum. High CSF levels of tau protein were associated with loss of integrity of fibres in the corticospinal tract; lower levels of amyloid-ß were associated with decreasing integrity of fibre tracts of the splenium and posterior cingulate gyrus. Volumetric investigations showed global atrophy of the white matter, but not the grey matter, and particularly not in temporal or mesiotemporal regions, as is typical in later stages of Alzheimer's disease.

conclusionsIn summary, alterations of neurodegenerative CSF markers in PMS individuals could be demonstrated which were correlated with structural connectivity losses of the corticospinal tract, the splenium, and the dorsal part of the cingulum, which can also be associated with typical clinical symptoms in these patients. These findings might represent a state of dysfunctional processes with ongoing degenerative and regenerative processes or a kind of accelerated aging. This study should foster further clinical diagnostics like tau- and amyloid-PET imaging as well as novel scientific approaches especially in basic research for further mechanistic proof.

Indexed as

Alzheimer Diseasetau ProteinsChromosome DeletionChromosome DisordersChromosomes, Human, Pair 22Diffusion Tensor ImagingHumansMagnetic Resonance Imagingtau ProteinsAmyloid-ßCerebrospinal fluidDTIDysfunctionMagnetic resonance imagingNeurodegenerationPhelan-McDermid syndromeSHANK3Tau-proteinWhite matter

Identifiers

PMID37670319
PMCPMC10481508
OpenAlexW4386446609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.